Agenda for Targovax Capital Markets Day 15 October 2018, in Oslo, Norway

Presentation of full TG01 phase I/II clinical trial results in resected pancreatic cancer, by Professor Daniel Palmer
Update on the TG mutRAS neoantigen vaccine development strategy
Review of recent ONCOS-102 interim data in melanoma and mesothelioma

OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, will host a Capital Markets Day in Oslo on Monday 15 October 2018, from 08:3010:15 

The event will include a presentation by a world leading expert on pancreatic cancer, Professor Daniel Palmer, who is the Chair of Medical Oncology at the University of Liverpool and Clatterbridge Cancer Centre. Professor Palmer has been involved in a number of large international clinical studies in pancreatic cancer and was the Principal Investigator of Targovax's TG01 phase I/II trial in resected pancreatic cancer, in combination with adjuvant gemcitabine. Top-line survival data from the trial were released in May 2018 (see press release here) and at the upcoming event Professor Palmer will present the full study results.

Event venue: Hotel Continental, Oslo, Norway

Date: 15 October, 2018

Time: 08:30 – 10:15 CET


08:15 – 08:30: Registration and breakfast

08:30 – 08:40: Welcome remarks, Øystein Soug, CEO, Targovax

08:40 – 09:20: Resected pancreatic cancer: overview and TG01 full data, Prof. Daniel Palmer

09:20 – 09:40: Update on TG strategy, Øystein Soug, CEO, Targovax

09:40 – 09:50: ONCOS overview, Dr. Erik Digman Wiklund, CBO, Targovax

09:50 – 10:10: ONCOS-102 interim data in melanoma and mesothelioma, Dr. Magnus Jäderberg, CMO, Targovax

10:10 – 10:20: Financial and closing remarks, Dr. Torbjørn Furuseth, CFO, Targovax

A live webcast of the symposium will be available in the Events and Presentations section of the Targovax website.

To register for the event, please contact  

For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47-922-61-624

Media and IR enquires:

Andreas Tinglum - Corporate Communications (Norway)
Phone: +47-9300-1773

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44-20-3727-1000

This information was brought to you by Cision,c2642877

Cision View original content:

SOURCE Targovax

Company Codes: Bloomberg:TRVX@NO, ISIN:NO0010689326, LSE:0RIS, Oslo:TRVX, RICS:TRVX.OL, Stockholm:TRVXO  

Back to news